Work Package 2 – Effectiveness

Objectives

  • To assess whether the selected neuroprotective drugs (brimonidine and somatostatin (SST)) administered topically are able to prevent or arrest neurodegeneration, as well as the development and progression of the early stages of DR.
  • To determine the prevalence of functional abnormalities related to neurodegeneration in those patients without or with minimal microvascular damage under ophthalmoscopic examination.
  • To compare the effectiveness of the selected drugs.
  • To identify those patients most prone to progressive worsening (characterisation of phenotypes and biomarkers).